Adolescent vaccination coverage in the United States continues to improve for HPV and for
meningococcal vaccines, with some disparities. Among adolescents living at or above the …

In 2018, adolescent vaccination coverage in the United States continued to improve for
meningococcal and HPV vaccines (primarily from increases among boys) and remains high …

In 2017, coverage among adolescents aged 13–17 years increased for≥ 1 dose of HPV
vaccine and≥ 1 and≥ 2 doses of meningococcal vaccines and remained high for≥ 1 dose …

In 2020, adolescent coverage with Tdap and the first dose of MenACWY remained high and
continued to improve for HPV vaccines, with some disparities. Adolescents living outside a …

To protect against vaccine-preventable diseases, including human papillomavirus (HPV)–
associated cancers, diphtheria, pertussis, tetanus, and meningococcal disease, routine …

To prevent diseases, including human papillomavirus (HPV)-associated cancers, pertussis,
and meningococcal disease, routine immunization of adolescents aged 11–12 years is …

At ages 11 through 12 years, the Advisory Committee on Immunization Practices (ACIP)
recommends that preteens receive 1 dose of tetanus, diphtheria, and acellular pertussis …

Among adolescents aged 13–17 years in 2021, HPV vaccination coverage (≥ 1 dose and
HPV vaccine up to date) increased. Coverage with≥ 1-dose Tdap and≥ 1-dose MenACWY …

In recent years, the Advisory Committee on Immunization Practices (ACIP) has
recommended three newly licensed vaccines: meningococcal conjugate vaccine (MCV4; 1 …

Three vaccines are routinely recommended for adolescents to prevent pertussis,
meningococcal disease, and cancers caused by human papillomavirus (HPV). CDC …